#kidney

Study findings suggest HCV-RNA-positive kidneys are not inferior in the direct-acting antiviral era.

The short treatment could make transplantation of organs from donors with HCV more safe, effective and economical.

Trial will assess antibody response in people who did not respond to two-dose regimen.

Researchers have called for revised treatment guidelines to address the higher risk of fracture in the HIV population.

Such kidneys are increasingly, and safely, being transplanted into people who do not have hepatitis C.

Study finds the two types of stroke, ischemic and hemorrhagic, have different risk factors.

A roundup of POZ’s reporting on studies presented at the Mexico City conference about HIV treatment, vaccines, PrEP and other concerns.

Swiss researchers analyzed shifts in kidney function among those switching from the old form of the HIV medication to the new one.

Transplantees can be treated safely and effectively for hep C, so greater education regarding such methods is in order.

A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco

A recent study found that transplanting such kidneys and then treating the recipient for hep C worked well.

People without hep C received kidney, liver or heart transplants from HCV-positive donors and then were treated for the virus.

Taking Vemlidy rather than Viread as prophylaxis against hepatitis B is tied to better markers of kidney and bone health.

Among those who switched their hep B treatment, Vemlidy may also be tied to a higher chance of ALT liver enzyme normalization.

In a recent study of Gilead’s Epclusa (sofosbuvir/velpatasvir), 92 percent of participants were on dialysis and 29 percent had cirrhosis.

Gilead Sciences has released multiple combo tablets that contain the updated tenofovir, which is linked to improved bone and kidney makers.